182 related articles for article (PubMed ID: 17595822)
1. [Ankylosing spondylarthritis--what is new in diagnosis and therapy?].
Kathmann W
Dtsch Med Wochenschr; 2006 Oct; Suppl 1():51-2. PubMed ID: 17595822
[No Abstract] [Full Text] [Related]
2. Whole-body magnetic resonance imaging evaluation of widespread inflammatory lesions in a patient with ankylosing spondylitis before and after 1 year of treatment with infliximab.
Appel H; Hermann KG; Althoff CE; Rudwaleit M; Sieper J
J Rheumatol; 2007 Dec; 34(12):2497-8. PubMed ID: 18061968
[No Abstract] [Full Text] [Related]
3. Inefficacy of infliximab in ankylosing spondylitis is correlated with antibody formation.
de Vries MK; Wolbink GJ; Stapel SO; de Groot ER; Dijkmans BA; Aarden LA; van der Horst-Bruinsma IE
Ann Rheum Dis; 2007 Jan; 66(1):133-4. PubMed ID: 17178760
[No Abstract] [Full Text] [Related]
4. Decreased clinical response to adalimumab in ankylosing spondylitis is associated with antibody formation.
de Vries MK; Brouwer E; van der Horst-Bruinsma IE; Spoorenberg A; van Denderen JC; Jamnitski A; Nurmohamed MT; Dijkmans BA; Aarden LA; Wolbink GJ
Ann Rheum Dis; 2009 Nov; 68(11):1787-8. PubMed ID: 19822712
[No Abstract] [Full Text] [Related]
5. [Axial spondyloarthritis and ankylosing spondylitis].
Nordström D; Kauppi M
Duodecim; 2010; 126(12):1467-74. PubMed ID: 20617750
[TBL] [Abstract][Full Text] [Related]
6. Fibromyalgia in between: where do the musculoskeletal physicians and psychiatrists stand?
Algül A; Basoglu C; Kiralp MZ; Ozçakar L
Acta Reumatol Port; 2008; 33(4):477-8. PubMed ID: 19107094
[No Abstract] [Full Text] [Related]
7. Treatment resistant ankylosing spondylitis with peripheral joint involvement - a case for infliximab?
Hrycaj P; Lacki JK
J Rheumatol; 2003 Jan; 30(1):204-6; author reply 206. PubMed ID: 12508417
[No Abstract] [Full Text] [Related]
8. When less is more.
Deodhar A
J Rheumatol; 2010 Jun; 37(6):1089-90. PubMed ID: 20516035
[No Abstract] [Full Text] [Related]
9. [Disease-modifying anti-rheumatic drugs for treatment of ankylosing spondylitis].
Madsen OR; Egsmose C
Ugeskr Laeger; 2009 Aug; 171(33):2268-72. PubMed ID: 19732504
[TBL] [Abstract][Full Text] [Related]
10. Could tumour necrosis factor blockers inhibit the progression of future structural damage in ankylosing spondylitis?
Gaspersic N; Sersa I; Jevtic V; Tomsic M; Praprotnik S
Ann Rheum Dis; 2008 Sep; 67(9):1354. PubMed ID: 18697784
[No Abstract] [Full Text] [Related]
11. The HLA-B*2709 subtype in a woman with early ankylosing spondylitis.
Olivieri I; D'Angelo S; Scarano E; Santospirito V; Padula A
Arthritis Rheum; 2007 Aug; 56(8):2805-7. PubMed ID: 17665436
[No Abstract] [Full Text] [Related]
12. Efficacy and safety of infliximab in patients with ankylosing spondylitis over a two-year period.
Braun J; Deodhar A; Dijkmans B; Geusens P; Sieper J; Williamson P; Xu W; Visvanathan S; Baker D; Goldstein N; van der Heijde D;
Arthritis Rheum; 2008 Sep; 59(9):1270-8. PubMed ID: 18759257
[TBL] [Abstract][Full Text] [Related]
13. Psoriasis, erythema nodosum, and nummular eczema onset in an ankylosing spondylitis patient treated with infliximab.
Delle Sedie A; Bazzichi L; Bombardieri S; Riente L
Scand J Rheumatol; 2007; 36(5):403-4. PubMed ID: 17963173
[No Abstract] [Full Text] [Related]
14. Acquired erythrocytosis upon treatment with infliximab for ankylosing spondylitis.
Antonelli M; Bupathi M; Janakiram M; Hergenroeder P; Khan MA
J Rheumatol; 2011 Mar; 38(3):581-3. PubMed ID: 21362796
[No Abstract] [Full Text] [Related]
15. TNF inhibitors for ankylosing spondylitis in the real world.
McVeigh CM; Bell AL; Cairns AP
Rheumatol Int; 2007 Dec; 28(2):199-200. PubMed ID: 17602229
[No Abstract] [Full Text] [Related]
16. Intraarticular injection of infliximab.
Sakellariou GT; Kakavouli G; Chatzigiannis I
J Rheumatol; 2006 Sep; 33(9):1912-3; author reply 1913. PubMed ID: 16960955
[No Abstract] [Full Text] [Related]
17. Mycosis fungoides in a patient with ankylosing spondylitis during infliximab therapy.
Sanli H; Ataman S; Akay BN; Yilmaz A; Yildizlar D; Gürgey E
J Drugs Dermatol; 2007 Aug; 6(8):834-6. PubMed ID: 17763616
[TBL] [Abstract][Full Text] [Related]
18. Predicting outcome in ankylosing spondylitis.
Pradeep DJ; Keat A; Gaffney K
Rheumatology (Oxford); 2008 Jul; 47(7):942-5. PubMed ID: 18492709
[No Abstract] [Full Text] [Related]
19. Analysis of response to infliximab in ankylosing spondylitis according to the axial and/or peripheral involvement: autoantibodies and drop outs are more frequent in the peripheral subset.
Maria Lizzio M; Peluso G; Zoli A; Gremese E; Tolusso B; Ferraccioli G
Ann Rheum Dis; 2007 Mar; 66(3):427-8. PubMed ID: 17311903
[No Abstract] [Full Text] [Related]
20. Mixed response to tocilizumab for ankylosing spondylitis.
Henes JC; Horger M; Guenaydin I; Kanz L; Koetter I
Ann Rheum Dis; 2010 Dec; 69(12):2217-8. PubMed ID: 20525837
[No Abstract] [Full Text] [Related]
[Next] [New Search]
